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ABSTRACT 




The immune system is of profound importance for host survival due to its ability 
to clear many acquired diseases. In case of infections and cancer, disease arises due to 
under-performance of immune system. Whereas in autoimmunity and transplantation, 
deleterious immunity to normal self-antigens and allogeneic antigens arises due to 
enhanced immune responses. Regulatory T (Treg) cells play a critical role in immune 
homeostasis in health and disease. 
Treg cells are important in the development and maintenance of immune 
tolerance towards self or transplantation antigens. However, Treg cells also play an 
obstructive role in cancer-related immunity by suppressing various effector cells. 
Therefore, development of immunomodulatory approaches that can either promote or 
inhibit expansion and/or suppressive function of Treg cells in the context of 
autoimmunity/transplantation and cancer/chronic infections, respectively, is of great 
importance. Treg cells require three signals, mediated by TCR-MHC-II1peptide (Signal 
1), co stimulation (signal 2) and cytokines (signal 3), for development, maintenance and 
function. Manipulation of any of these signals, therefore, may present an effective 
approach in modulating Treg cells in the context of various disease settings. The goal of 
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this dissertation is to exploit signal 2 for modulating Treg cells in the setting of cancer 
and transplantation for immunotherapy. 
We chose the 4-1 BB signaling pathway because of its constitutive expression on 
Treg cells and its important role in both innate and adaptive immunity. Using a chimeric 
4-1BBL (SA-4-1BBL), we herein show that signaling through 4-1BB inhibits antigen and 
TGF-~ driven conversion of Teff into Treg cells. This effect is primarily mediated by 
SA-4-IBBL-induced IFN-y production in Teff cells. Importantly, vaccination of mice 
with established ovalbumin (TAA) expressing EG.7 tumors with SA-4-1BBL results in 
the blockade of Teff cell conversion into Treg cells within the tumor and spleen. In 
contrast, SA-4-1BBL in the presence of IL-2 and rapamycin promotes the conversion of 
naIve CD4+ T cells into Treg cells. Provision of three signals (allogeneic TCR 
stimulation, 4-1BBL mediated co-stimulation, and IL-2 cytokine) in the presence of 
rapamycin was effective in enhancing the generation/expansion of Treg cells. This is 
unique to 4-1BB as signaling through CD28 did not increase the generation of Treg cells. 
Collectively, these novel functions of soluble form of SA-4-1 BBL represent a promising 
approach to inhibit/promote Treg cell generation/expansion with potential therapeutic 
applications in cancer immunotherapy and transplantation. 
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Regulation of immune system is of profound importance to host survival. In 
settings of autoimmunity or cancer, control is lost, resulting in hyper or hypo activation 
of immune system respectively. Suppression of deleterious immunity to normal self-
antigens in autoimmune diseases, establishment of immunological tolerance to allogeneic 
transplants and reversal of the unresponsive state and enhancing immune responses to 
autologous tumor cells or chronic infections are essential for effective immunotherapy. 
Regulatory T (Treg) cells play an essential role in the establishment and maintenance of 
peripheral tolerance (1). There is now convincing evidence that defect in the numbers 
and/or function of Treg cells can lead to autoimmunity and graft rejection, whereas an 
excess of Treg cells can inhibit anti-tumor and anti-pathogen immunity (1-8). Therefore, 
there is an immediate need for the development of immunomodulatory approaches that 
can promote expansion of Treg cells in the context of autoimmunity and transplantation 
and also inhibit the expansion and/or suppressive function of Treg cells in the context of 
cancer and chronic infections. Signaling pathways required for the regulation of Treg 
cells might represent efficient targets for designing Treg cell-based immumodulatory 
approaches for the treatment of these diseases. 
These are signal 1 delivered via T -cell receptor (TCR) and major 
histocompatibility complex (MHC) molecules/peptide interactions, which needs 
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to be accompanied by costimulation delivered via CD28 receptor family (9). Treg cells 
than get activated and need cytokines, particularly IL-2, for expansion and acquisition of 
effector function (10). A series of recent studies, including those from our laboratory, 
have demonstrated that several members of the tumor necrosis receptor (TNFR) family 
can provide co stimulation to Treg cells for their expansion and survival (11-13). In 
particular, we demonstrated that costimulation via 4-1 BB receptor has diverse functions 
on Teff and Treg cells with therapeutic implications in cancer, transplantation, and 
autoimmunity (12-16). Thus the aim of this dissertation is to exploit 4-1BB/4-1BBL 
signaling as a novel immunomodulatory approach for manipulating Treg cells m an 
attempt to modulate immune responses in cancer and transplantation settings. The 
rationale for focusing on 4-1BB/4-1 BBL pathway is because of its critical role in 
regulating both T effector (Teff) and Treg cell responses that can be tuned for the 
treatment of disease. In the case of cancer or infectious diseases, preferential reduction of 
Treg cell numbers and/or blocking their function may enhance antitumor/pathogen 
immunity. However, in case of transplantation, preferential augmentation of Treg cell 
numbers and/or function may help suppress autoimmune responses and facilitate the 
establishment of tolerance to allogeneic antigens. 
Regulatory T cells 
The primary function of the immune system is to protect the body from foreign 
pathogens. This requires the immune system to recognize a countless number of antigens 
along with its ability to differentiate between self and non-self (17). Thymus plays a 
critical role in generating an extensive repertoire of T cells to recognize these antigens by 
positive selection based on TCR avidity (18). Along with that, a passive central tolerance 
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mechanism also exists in the thymus where self reactive cells are deleted by a process 
called clonal deletion or negative selection (19). However, self reactive T cells escape 
into the periphery and exist in healthy individuals without causing autoimmune diseases. 
This is because several regulatory mechanisms, such as clonal deletion (20), anergy (21) 
and suppressive cytokines (22) exist in the periphery to keep in check the pathogenic self-
reactive T cells. 
In addition to these acquired peripheral tolerance mechanisms, the presence of 
natural tolerance through a T cell population called naturally occurring T regulatory 
(nTreg) cells, identified by the expression of CD4 and FoxP3 markers, has been 
established (1). These cells play a critical role in self tolerance as demonstrated by the 
presence of severe and uncontrolled autoimmunity in mice and patients that lack these 
cells (23-27). Although the primary function of these cells in the periphery is to control 
self-reactive pathogenic Teff cell function and collateral damage as a result of 
uncontrolled immune responses to infections, thereby contributing to immune 
homeostasis, a series of published evidence indicate that Treg cells can contribute to 
disease by either positively or negatively affecting the ongoing immune responses such as 
in cancers and autoimmunity, respectively (3, 5, 7, 28-36). 
nTreg cells are selected and generated in the thymus through high avidity 
interactions between MHC class II and TCR (10, 37-42). The first evidence that nTreg 
cells are selected in the thymus came from studies demonstrating the existence of a subset 
of CD25+ cells in the CD4 single-positive thymocyte compartment in thymus of both 
humans and mice (43-45). These CD25+CD4+ thymocytes were capable of suppressing 
the function of Teff cells in vitro as well as in vivo in adoptive transfer models (43). 
Importantly, these cells under normal physiological conditions also exhibited increased 
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expression of various activation markers, such as CTLA-4, GITR, Pas, and OX-40 (44, 
46) that are normally expressed on activated Teff cells, suggesting that Treg cells may 
always be in a semi-activated phenotype, plausibly due to constant control of potential 
autoreactive effector peripheral mechanisms. 
TCR signaling is indispensable for T cell lineage commitment of Treg cells 
during their development in the thymus. The role of TCR in the development of 
Treg cells is best demonstrated by the finding that TCR-transgenic mice on RAG-1-
background (recombination-activating gene-deficient mice which lack endogenous TCR 
rearrangements) do not develop Treg cells, whereas most TCR-transgenic mice on non-
RAG-1- background develop Treg cells (18, 47). Apart from TCR signaling, 
costimulatory signals mediated by CD28/CD80 or CD86 are important in determining the 
repertoire and size of the Treg cell compartment in the periphery even though this 
signaling is not required for their function (9). Mice lacking either CD28 or CD80 and 
CD86 have decreased Treg cells in the periphery (9). This decreased Treg cell 
compartment is attributed to the direct role of CD28 signaling on thymocyte development 
of Treg cell and also due to diminished peripheral IL-2 produced by T cells in the 
absence of CD28 co stimulation (48). Apart from TCR and CD28 signaling, dependence 
of Treg cells on IL-2 has been linked to their development, maintenance, survival and 
expansion of the Treg cell population (49). Deficiencies in either IL-2 or IL-2R is 
manifested by severe autoimmune disorders marked by excessive lympho proliferation 
(50). However, adoptive transfer of splenic or thymic CD4+ T cells from IL-2-deficient 
mice, but not from CD25-deficient mice, into a TCR-transgenic model of experimental 
allergic encephalomyelitis (EAE) showed that these Treg cells can protect from 
developing EAE. Thus, it suggests that Treg cell can development and undergo lineage 
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commitment in the thymus in the absence of IL-2. However, signaling through IL-2 
receptor is essential for their activity. 
Both humans and mice develop a fatal autoimmune disorder (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked - IPEX in humans and scurfy 
in mice) due to mutations in the gene encoding FoxP3 transcription factor, strengthening 
the importance of this molecule in the development/function of Treg cells (24, 27, 51, 
52). In humans, this immune disorder is marked by massive lymphoproliferation, onset 
of Type 1 Diabetes, thyroiditis and food allergies. Additionally, some patients develop 
other autoimmune pathologies like hemolytic anemia and thrombocytopenia, eczema, 
severe enteropathy as well as severe infections (51). Scurfy mutant mice lacking 
functional FoxP3 do not develop Treg cells and show various autoimmune pathologies 
(53, 54). FoxP3 protein belongs to a family of transcription factors that display a similar 
domain called winged helix-forkhead DNA-binding domain (forkhead box - Fox). 
FoxP3 transcriptional factor bind to the promoter DNA of various genes, acting as a 
transcriptional regulator (most suppressor) for various cytokines such as IL-2, IL-4 and 
TNF (55). In the absence of other cell surface molecules that are specific for Treg cells, 
FoxP3 expression is used as the sole marker for the identification of Treg cells for mice. 
However, this is not the case for human as newly activated human Teff cells also 
transiently express FoxP3 (56-60) and as such the identification of human Treg cells 
require testing their suppressive function for confirmation. 
The role of nTreg cells in the maintenance of peripheral tolerance has been 
extensively studied. This is illustrated by spontaneous development of autoimmune 
diseases by the depletion of Treg cells in normal animals and restoration of these cells in 
tum prevents the development of the disease (1, 61). For example, Treg cell depleted 
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spleen cells from nonnal mice cause spontaneous autoimmune disease in multiple organs 
following adoptive transfer into syngeneic T-cell-deficient hosts (62-64). 
Functional/physical elimination of Treg cells in setting of cancer has therapeutic 
implications (34). For example, depletion of C4+CD2S+ T cells before tumor challenge is 
effective in eliciting potent tumor specific immunity in vivo along with the development 
of various autoimmune diseases (34). Thus, nTreg cells are not only effective in 
inhibiting autoimmunity but also block/suppress a variety of physiological and 
pathological immune responses to non-self antigens that manifest in acquired diseases. 
In recent years, it became evident that in addition to nTreg cells that are generated 
m the thymus, another population of CD4+FoxP3+ T cells with regulatory function 
develop from the conversion of naIve CD4+ T cells outside the thymus under various 
settings (6S-67). This so called adaptive or induced (iTreg) cells behave in a similar 
manner to the nTreg cells in suppressing immune responses. The first set of evidence for 
the existance of this cell type came from adoptive transfer experiments where naIve 
CD4+CD2S- T cells were transferred to lymphopenic mice or mice devoid of nTreg cells 
(SO, 68). During the homeostatic expansion of the transferred cells, part of the population 
acquired FoxP3 expression and suppressive function. Induction of iTreg cell in vivo by 
foreign antigens was also shown in mice treated with minute antigen doses (6S). iTreg 
cells can also be induced in vitro from naive CD4+ T cells, particularly in the presence of 
TCR stimulation and TGF-~ and IL-2 cytokines (66, 69). Thus, it is clear that naive 
CD4+ T cells selected as FoxP3- in the thymus have full potential to become 
FoxP3+ iTreg cells in vivo and in vitro (Figure 1). These cells are critical to acquired 
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peripheral tolerance as well as exploited for immune evasion by cancer and infections or 
experimentally for tolerance to auto and alloantigens for therapeutic purposes. 
Generation of iT reg cells 
Unlike nTreg cells, which develop in a highly controlled thymic microenvironment (70), 
generation of iTreg cells may vary based on the environmental cues or conditions. Initial 
evidence of peripheral conversion came from adoptive transfer experiments where sorted 
polyclonal naive CD4+CD2Y T cells transferred into lymphopenic mice or TCR 
transgenic mice on RAG-1- background, which lack nTreg cells, were shown to convert 
into FoxP3 expressing iTreg cells (50, 68). Under those settings, where homeostatic 
proliferation of the transferred cells was possible, part of the donor population 
became CD2S+ and FoxP3+ and they also expressed Treg cell specific markers CTLA-4 
and GITR along with their suppressive capability. In a different setting, transfer of 
antigen-specific naive CD4+ T cells into lymphocyte-deficient RAG-1- mice that expressed 
the antigen as a systemic secreted protein resulted in acute immune response from 
transferred cells towards the recipient. This was followed by a tolerogenic phase that is 
associated with iTreg cell generation (71). This iTreg cell generation did not require 
the thymus but was dependent on IL-2. Although the precise developmental 
requirements of iTreg cell generation in vivo is still incomplete, some studies successfully 
generated iTreg cells in vivo by treating mice with low doses of antigen cross-linked to 
DEC-20S Ab (targets antigens specifically to DCs) and delivered by osmotic pump. 
Conversion of CD4+CD2S- T cells into iTreg cells was also shown in another adoptive 
transfer model where sorted CD4 cells were transferred into irradiated mice (72). Under 
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these lymphophenic conditions, these cells readily underwent conversion and this was 
independent of thymus, but was dependent ofCD28 signaling. 
In vitro generation of iTreg cells reqUIres both TCR stimulation and the 
cytokines TGF-~ and IL-2 are absolutely required for naYve CD4+ effector cells to 
convert into iTreg cells. During TCR-stimulation, addition ofTGF-~ to naive 
CD4+ T cells cultures induces the expression of FoxP3 (66) and the mechanism involves 
cooperation of the transcription factors STAT3 and NF AT at a FoxP3 gene enhancer 
element (69, 70). Addition ofTGF-~ along with CD3 and CD28 stimulation to naive 
CD4+ T cells induced the generation of iTreg cells which were anergic and suppressive in 
vitro and in vivo as shown by their ability to suppress inflammation in an 
experimental asthma model (66). As discussed in the nTreg cells section, IL-2 is 
dispensable for the generation of nTreg cells in the thymus. However, for in vitro 
generation of iTreg cells, IL-2 is required. Studies done by neutralization IL-2 in the 
cultures or using IL-2-deficient T cells demonstrated that IL-2 is required for in vitro 
for induction of FoxP3 mediated by TGF-~ (73). IL-2 signaling is required for the 
activation of STAT5, which in tum binds to FoxP3 gene enhancing its expression. 
Costimulatory signal mediated by CTLA-4 is dispensable for thymic generation of nTreg 
cells (74). However, upregulation ofCTLA-4 is required for TGF-~ mediated expression 
of FoxP3 in naYve CD4+ T cells and also for suppressive activity of converted iTreg cells 
(74). 
Differences between nTreg and iTreg Cells 
There has been some disagreement on whether in vitro generated iTreg cells are as good 
suppressor cells as nTreg cells (28, 33, 66, 75-77). The functional difference between 
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nTreg cells and iTreg cells looks to arise from the methylation of CpG motifs in the 
FoxP3 locus where nTreg cells have complete demethylation upstream of exon 1 and is 
unique to FoxP3+ Treg cells. In contrast to nTreg cells, in vitro generated iTreg cells 
display partial demethylation even though they have high F oxP3 expression (78). These 
in vitro generated iTreg cells, but not nTreg cells, lost both FoxP3 expression and 
suppressive activity when restimulated in the absence ofTGF-B (79, 80). A marked 
difference in the methylation state of iTreg cells generated in vitro and in vivo is that in 
vivo iTreg cells generated by administration of antigen displayed efficient demethylation 
(78) and are effective suppressors as compared to in vitro generated iTreg cells (65, 71, 
81-83). Using gene profiling, studies have defined pool of genes that are specifically 
expressed in nTreg cells. Some of these genes are regulated independently by FoxP3 and 
some of them are repressed or induced exclusively by FoxP3 (76). Comparing this subset 
of genes that are either upregulated or downregulated between nTreg cells and iTreg cells 
showed that in vitro generated iTreg cells did not display some of the nTreg cell signature 
genes (76). 
As iTreg cells are generated in the periphery from naIve CD4+ T cells, nTreg and 
iTreg cells might have potential differences in terms of TCR repertoire, differentiation 
and their mode of action. Studies have indicated that iTreg cells mediate their inhibitory 
function by producing immunosuppressive cytokines like TGF-B and IL-lO (84, 85). 
Contrastingly, nTreg cells are shown to function by direct cell-cell interactions with 
responding T cells or APCs and this mechanism is cytokine-independent (86). 
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iT reg cells and Cancer 
Recent progress in understanding the ability of innate and adaptive immune responses 
against tumors has strengthened the concept of immunosurveillance. For example, the 
incidences of tumor in immune-incompetent individuals either via acquired genetic 
defects or experimental/therapeutic manipulations are significantly higher than 
individuals with normal functions (87). Most importantly, a recent study has 
demonstrated using a spontaneous mouse model of melanoma that tumor cells 
disseminate throughout the body early in development of the primary tumor and stays 
dormant for varying periods of time depending on the tissue. Most importantly, 
dormancy in the lung was associated with reduced proliferation of the disseminated 
tumor cells by CD8+ T cells as physical elimination of these immune cells resulted in 
accelerated tumor growth (88). Irrespective of active immunosurveillance, tumors grow 
in immune-competent individuals suggesting that immune system and tumors exist in an 
equilibrium state. This is primarily due to the ability of tumors to exploit various 
immune evasion mechanisms for growth and progression. This is evidenced by studies 
demonstrating the presence of tumor-specific and activated both CD4+ and CD8+ T cells 
in cancer patients without functional consequences with respect to clinical disease (89). 
These observations suggest that immune system in patients with cancer is constantly on 
attack, but there are other counter-attack mechanisms that tilt the balance towards 
immune inactivation and tumor progression. 
Tumors employ multiple mechanisms for evading T cells responses. Some of 
these include alterations of components of the antigen presentation machinery, secretion 
of inhibitory factors, activation of negative regulatory pathways, and recruitment of Treg 
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cell populations (90-93). Treg cells represent one of the most dominant immune evasion 
mechanisms employed by tumors for progression. Increased numbers of Treg cells in 
tumor tissue and/or peripheral blood of patients with various cancers have been reported 
(2, 4, 35, 94, 95) and this is associated with poor prognosis and survival (2). Dominant 
role of Treg cells in immune evasion mechanisms is evident from various experimental 
tumor models, where depletion of these cells or modulation of their function significantly 
improved the therapeutic efficacy of the vaccines (36, 96-98). Blocking antibodies 
against some of the signature costimulatory molecules expressed by Treg cells like 
CTLA-4 and GITR were able to induce potent antitumor immunity and this was 
associated with increased number of tumor-specific interferon-y-secreting CD4+ and 
CD8+ T cells in the spleen (98, 99). Strikingly, a combination of blocking antibodies 
against both CTLA-4 and GITR synergistically enhanced anti-tumor responses and was 
able to eradicate more advanced tumors in mice (98). Tumors are known to suppress 
immunity by promoting the chemokine mediated recruitment followed by cytokine 
mediated expansion, and activation of Treg cells (100). This specific recruitment of Treg 
cells results in the inhibition of effector T cell activation, immune escape, and ultimately 
tumor progression (3). Interestingly, many tumors are known to produce cytokines such 
as IL-I0 and TGF -~, which promote the proliferation of nTreg cells, and as well as the 
conversion of CD4 T cells into iTreg cells (3, 101, 102). Conversion of naive CD4+ 
T cells into iTreg cells and their accumulation in tumor sites (5, 103) also playa key role 
in obstructing tumor immunosurveillance and cancer immunotherapies (8, 103). In one 
study, it has been reported that cyclooxygenase (COX)-2 and its product 
prostaglandin play an important role in the pathogenesis of non-small cell lung cancer 
(104). COX-2 along with its product, prostaglandin produced by tumors induced the 
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expression of FoxP3 in T cells, and consequently increased Treg cell activity in the tumor 
(l05). Furthermore, inhibition of COX-2 reduced Treg cell frequency and activity in the 
tumor and attenuated FoxP3 expression in tumor infiltrating lymphocytes along with 
decreased tumor burden. The effective approach for cancer immunotherapy will depend 
on the identification of unique cell surface receptors or ligands that can greatly enhance 
the effector responses against cancer but also inhibit the suppressive function of Treg 
cells and also conversion of naIve CD4+ T cells into iTreg cells. In this context, signaling 
via the members of TNFR costimulatory molecules may have the potential to control the 
function as well as generation of iTreg cells in settings of vaccines with potential 
therapeutic efficacy. 
iTreg cells and transplantation 
In the last two decades transplantation of organs, tissues, or cells between genetically 
non-identical individuals has become a routine therapeutic option for many disorders 
such as organ failure, cancers and other hematological malignancies. However, 
transplantation of allogeneic tissue is associated with secondary diseases arising from 
graft-versus-host (GVH), in case of bone marrow cell transplant or transplantation of 
tissues rich in mature lymphocytes, or host-versus-graft (HVG), in case of all foreign 
transplants, immune responses. These responses develop when immune cells of the graft 
or recipient recognize allogeneic histocompatibility antigens and mount an immune 
attack against the recipient or donor, respectively. During this activation, proliferation of 
effector cells along with the release of proinflammatory cytokines result in tissue damage 
(l06). The discovery of immunosuppressive drugs for the prevention of GVH and HVG 
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immune responses, paved the way for the clinical use of allogeneic transplantation as a 
curative modality for treating various disease states. 
Despite this accomplishment, GVH disease, graft rejection, and opportunistic 
infections due to prolonged nonspecific imm~nosuppression following 
transplantation remain the major hindrance limiting the efficacy of allogeneic 
transplantation. Studies show that allogeneic graft rejection (HVG) can be mediated by 
host CD4+ and CDS+ T cells (107), NK cells (10S), NKT cells (109) and yo T cells (110, 
111) that can recognize histocompatibility antigens of the donor cells. In order to 
overcome this, patients are treated with immunosuppressive drugs such as calcinurin and 
mammalian target of rapamycin (mTOR) inhibitors. Whereas, GVHD requires that the 
graft contain immunocompetent cells before transplantation, and there must be 
histocompatibility differences in antigens between host and the donor which will 
ultimately lead to donor immune response to host. Both CD4+ and CDS+ T cells mediate 
the effector pathway in the onset of GVHD and HVGD using multiple direct, such as 
killing of target via mechanisms perf orin and FasL (112), or indirect mechanisms, such as 
proinflammatory cytokines, delayed type hypersensitivity reactions, generation of 
humoral immunity. 
To overcome complications associated with allogeneic transplantation and permit 
engraftment, recipients and grafts undergo a series of conditioning procedures. The 
primary purpose of this conditioning is to suppress host immunity to prevent graft 
rejection by reducing the immunocompetent cells. To this purpose, hosts are treated with 
myeloablative drugs and total body irradiation that are cytotoxic in nature (113). 
Following transplantation, recipients are treated chronically with immunosuppressive 
agents to prevent graft rejection as well as control GVHD. Use of cytotoxic conditioning 
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and immunosuppressive drugs are often associated with toxicity and side effects reducing 
the efficacy of transplantation and decreasing the overall survival (114). Therefore, the 
development of novel immunosuppressive regimens with minimal/tolerable toxicity is of 
critical importance and focus of the transplantation field. 
The activities of Treg cells are now recognized as fundamental to the 
development and maintenance of immune tolerance and shown to inhibit alloreactive T-
cell activation and effector cell function (6, 115), serving as an attractive therapeutic tool 
for inducing tolerance against transplanted grafts (116, 117). Despite decades of research 
into the phenotypes and functions of different subsets of Treg cells, only recently have 
they been sufficiently well characterized to begin considering how they might be targeted 
therapeutically. There are numerous reports that by manipulating the numbers and/or 
function of Treg cells in mice, we can decrease pathology in a wide range of contexts, 
such as autoimmunity and transplantation. Transplantation in sublethally conditioned 
mice along with donor Treg cell infusion was shown to prevent graft rejection and 
suppress the onset of acute GVHD (30-32, 118, 119). Conversely, depletion of Treg cells 
from either graft or recipients following transplantation enhances the rate of graft 
rejection and development of GVHD (31, 118). Treg cells are present in relatively low 
frequencies in lymphoid organs. For efficient use of Treg cells for inducing tolerance in 
transplantation setting, studies have focused on developing strategies for both ex vivo and 
in vivo expansion of Treg cells (7). In some settings, both ex vivo expansion of Treg cells 
and subsequent activation of Treg cells to increases their suppressor cell potency was 
shown to inhibit the onset of GVHD (119). Although expansion strategies that can target 
in vivo expansion of Treg cells will be safer and clinically relevant, they remain to be 
developed. 
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Many transplantation protocols reqmre use of immunosuppressive agents like 
calcineurin inhibitors cyclosporine A and mTOR inhibitor, rapamYClll. These 
immunosuppressive agents influence the Treg cell expansion strategies as they have both 
negative and positive effects on Treg cells. For example, calcineurin inhibitors block the 
production of IL-2, in tum reducing the Treg cell proliferation, function and expansion 
due to their critical dependence on IL-2 (120). There the use of calcineurin inhibitors are 
associated with nonspecific suppression of both Teff and Treg cells with the requirement 
of continuous use in the patients with long-term adverse consequences. Therefore the use 
of such nonspecific immunosuppressant has recently been called into question for the 
ultimate goal of achieving clinical transplantation tolerance. Therefore, there is an 
intense interest in developing immunosuppressive drugs that preferentially inhibit the 
function of Teff cells with no or positive effects on Treg cell development and function. 
Rapamycin, a mTOR inhibitor, appears to suffice this promise. 
Rapamycin is a potent immunosuppressant and an inhibitor of T cell proliferation. 
It acts on a serine/threonine protein kinase (mTOR) that has an important 
immunomodulatory function in both innate and adaptive immune responses. mTOR 
plays a crucial role in cell growth and proliferation, transcription, translation, ribosomal 
synthesis, and cytoskeleton organization (121). Rapamycin is produced by Streptomyces 
hygroscopicus and was first identified as a potent antifungal agent (122). Later it was 
found to exhibit potent immunosuppressive activity and inhibit cell proliferation. It is 
currently used as an immunosuppressive drug in renal transplantation (123) and for the 
prevention of graft rejection and GVHD in various transplantation settings (124, 125). It 
is also used as a chemotherapeutic agent for treatment of various cancers (126). 
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Unlike other immunosuppressive agents in the context of transplantation, 
rapamycin has two fold advantage that it not only suppresses the proliferation of T cells, 
but also helps the generation of iTreg cells and does not affect the proliferation of nTreg 
cells (127), indicating that Treg cells are not prone to mTOR inhibition. Unlike other 
immunosuppressive agents, rapamycin does not alter the immunosuppressive ability of 
Treg cells in in vitro cultures (128). In vivo administration of rapamycin results in 
increased Treg cells numbers compared to CD4+ Teff cells (128, 129). In addition, 
rapamycin in combination with IL-2 was effective in selectively expanding Treg cells 
from a mixed CD4+ T cell population in vitro (130). In another study, the observation 
that stimulating CD4+ T cells in the presence of rapamycin results in induction of 
suppressor functions in conventional CD4+ T cells offered an explanation that rapamycin 
not only promotes survival and function of nTreg cells, but also induces FoxP3 
expression in CD4+ T cells by converting them into iTreg cells (131). TGF -~ induces 
FoxP3 expression through the activation of the transcription factor SMAD3 (mothers 
against decapentaplegic homologue 3), which in combination with NF A T binds to the 
enhancer region of FoxP 3, ultimately resulting in its transcription (132). Under 
physiological conditions, signaling through mTOR results in inhibition of SMAD3 
activation in Teff cells (133), which can be inhibited by rapamycin, leading to the 
activation of SMAD3 and expression of FoxP3. Now the cause of a generalized increase 
in the frequency of Treg cells in the presence of rapamycin can be interpreted as a result 
of two effects: 1) the ability ofnTreg cells to expand in the presence ofrapamycin, and 2) 
the promotion of FoxP3 expression in CD4+ T cells. Rapamycin, therefore, is viewed as 
a tolerogenic drug that can be used in combination with other therapeutic approaches in 
transplantation and autoimmune diseases aimed at inducing Treg cells. Particularly, the 
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ability of rapamycin to suppress the function of Teff cells not only is important for the 
generation of a time window required for the generation of regulatory mechanisms, but 
also serves to suffice the FDA requirement for the use of standard immunosuppression 
for transplant patients. The dual ability of rapamycin to suppress the function of Teff 
cells and facilitate the generation of Treg cells makes it as the drug of choice for 
immunomodulation. Most importantly, rapamycin also has immunoregulatory functions 
on antigen-presenting cells, such as DCs (134), further enhancing its use for the 
generation of tolerance. 
4-1BB/4-1BBL signaling pathway and immune regulation 
The specificity of T cells responses are controlled by a series of orchestrated signaling 
pathways. First, the engagement of TCR with MHC/ Ag complex determines the 
specificity of the immune response (135). However, other signals such as costimulation 
(CD28-B7) and cytokines (IL-2) are required for full activation of T cells (135). In the 
absence of these signals, T cells usually undergo antigen specific immune down 
regulation, called anergy (136). After the initial activation, T cells go on and differentiate 
into effector cells of which some will survive as long-lived memory T cells (137). After 
the initial activation, T cells upregulate various members of the TNFR family 
costimulatory molecules and uses signaling via these receptors for survival, proliferation, 
expansion, and differentiation to acquire effector and long-term memory functions. 
TNFR family members such as, CD27, CD134 (OX40), CD137 (4-1BB), HVEM, 
CD30, F AS and GITR play a direct role in T cell responses leading to initial T cell 
activation. TNFR members are divided into various groups based on the intracellular 
domains or factors that are associated with these receptors. For example, receptors like 
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F AS are associated with death domains (DD) and signaling through these receptors 
activate the caspase cascade, ultimately leading to apoptosis (11). Importantly, some of 
the TNFR members such as 4-1BB and OX40 are associated with TNF receptor 
associated factors (TRAF) which play an important role in T cell activation, survival and 
differentiation (11, 138, 139). 
4-lBB (CDI37, TNFSFR9) is a member of the TNF receptor family which was 
initially shown to play an important role as a costimulatory molecule for both CD4+ and 
CD8+ T cells (140). 4-lBB is expressed on activated CD4+ and CD8+ T cells thereby 
controlling their proliferation, survival and cytokine production (141, 142). Additionally, 
this receptor is also expressed by activated NK cells, neutrophils, eosinophils, subsets of 
immature/mature DCs in human as well as mice (136, 143-147). Its ligand, 4-1BBL is 
expressed by activated professional APCs (143, 148, 149) as well as other non-immune 
cells such as smooth muscle cells and endothelial cells (150). Thus, regulation of T cell 
responses by 4-1BB signaling most likely occurs by the engagement of 4-1BBL on 
activated APCs with 4-lBB on activated T cells, ultimately resulting the activation of T 
cells, their survival, expansion, and conversion to effectors and long-term memory cells. 
The engagement of 4-1 BBL with 4-1 BB may transduce the signal not only to T 
cells for immune activation, but also reverse signaling into APCs with both positive 
immune consequences. Reverse signaling through 4-1 BBL can occur in DC, B cells, and 
monocytes (151, 152), suggesting the role of this signaling pathway on multiple cell 
types with multiple functions. The role of 4-1 BBL reverse signaling is best illustrated in 
human DCs where 4-1BBL cross-linked on DCs with CD137-Fc led to DC maturation in 
a TNF -u dependent manner (153). Reverse signaling of 4-1 BBL also up-regulated 
chemokine receptor CCR7, thereby mediating the migration of DC. Finally, CD137L-
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activated DCs were able to induce T cell differentiation and proliferation along with the 
production of proint1ammatory cytokines IL-12 and IFN-y. Most importantly, a recent 
report has demonstrated that reverse signaling converts human monocytes into functional 
Des (154). Collectively, these data demonstrate that the 4-1BB/4-IBBL signaling 
system tunes the immune system at multiple effector cell types for the generation of 
effector immune responses to cancers and infections. 
The kinetics of 4-1 BB expression in vitro reveal that the expression on T cells 
peaks at about 48 hr after primary T cell activation and declines again after 4-5 
days (140, 155, 156). However, in vivo analysis of 4-lBB expression reveals that its 
expression on T cells can be earlier, peaking at 12-36 hrs and is more transient as 
compared to in vitro kinetics (157). This expression pattern coincides with the T cell 
activation kinetics and fall between the expression of activation markers, CD69 and 
CD44 (158). In addition to its role as an activation-induced costimulatory receptor on T 
cells (156), 4-1 BB is also expressed constitutively on Treg cells (159, 160) with potential 
function of regulating the balance between Teff and Treg cells with important 
implications in health and disease. 
The ability of costimulatory TNFR family members like 4-1 BB to regulate both T 
cell and Treg cell activation, survival and differentiation at different stages in the immune 
response make these molecules potential targets for various immunomodulatory 
approaches for the treatment of various cancer and graft rejection and tolerance induction 
to autoantigens. The potential of 4-1 BB as a target for immunomodulation in the cancer 
setting arises from the findings that it can greatly enhance the expansion of CD4+ and 
CD8+ T cells in vivo (14, 140, 158, 161) and its ability to make these cells to be 
refractory to Treg cell mediated immunosuppression (12, 159). We recently showed that 
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when 4-1 BBL was used as a component of vaccine against vanous tumor models 
increased the number of both CD4+ and CD8+ T effector as well as memory responses 
(15) along with a decrease in intratumoral Treg cells with therapeutic efficacy in various 
tumor models. It is not clear at this point how 4-1 BB signaling leads to a better ratio of 
Teff/Treg cells within the tumor and lymphoid organs. Signaling via 4-1BB may 
preferentially expand Teff cells, actively inhibit the generation of iTreg cells, and/or 
preferentially cause Treg apoptosis. Regardless, our recently published studies in tumor 
setting using 4-1BB costimulation as a means of immunomodulation are exciting and 
further substantiate the importance of this pathway for modulating immune responses for 
therapeutic purposes. 
The potential use of 4-1 BB signaling as a target for immunotherapy in context of 
transplantation and autoimmunity arises from the constitutive expression of 4-1 BB on 
Treg cells and the ability of signaling via this receptor to effectively expand nTreg cells 
ex vivo without losing their suppressive ability and FoxP3 expression (12, 162). Our 
laboratory has recently demonstrated that sorted nTreg cells constitutively express 4-1 BB 
receptor and respond to IL-2 by upregulating the level of this receptor (12). Most 
importantly, Treg cells were expanded over 110 fold within a few weeks by periodic 
stimulation with low dose exogenous IL-2 and a chimeric form of 4-1BBL, SA-4-1BBL. 
The expanded cells had potent suppressor function on Teff cells as demonstrated in vitro. 
Importantly, adoptive transfer of the expanded Treg cells in a chemically diabetic 
allogeneic islet model resulted in effective prevention of graft rejection and glucose 
homeostasis (12). These findings along with the ability of rapamycin and IL-2 to expand 
nTreg cells and/or convert naIve CD4+ T cells into iTreg cells led us to hypothesize that 
targeting 4-1 BB in the transplantation and autoimmunity settings in the presence of 
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rapamycm may serve as a viable approach to expand Treg cells in vivo for 
immunotherapy. 
In conclusion, 4-1BB signaling has great potential as an immunomodulatory 
approach to shift the balance between Teff and Treg cells for the treatment of diseases 
that can benefit from a predominant form of one of these cell types. Therefore, the main 
focus of this PhD study is to test the utility of 4-1 BB signaling for either expanding or 
contracting Treg cell numbers in inverse correlation with the number of Teff cells with 
the ultimate goal of treating cancer, autoimmuity, and graft rejection. 
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Figure 1. Development of nTreg and iTreg cells_ nTreg cells are selected based on 
TCR-MHC interactions in the thymus and migrate to periphery for the control of 
autoimmunity. In marked contrast, iTreg cells are generated de novo in the periphery 
from conventional naIve CD4+ T cells. Although the precise mechanism responsible for 
the generation of iTreg cells is not well elucidated, TGF-~ and IL-2 appear to be play 
important roles. These Treg cells use various mechanisms to control the function of cells 






































Figure 2. Pleiotropic effects of 4-1 BB signaling on the regulation of development and 
function of nTreg and iTreg cells. The 4-1BB signaling contributes to the proliferation, 
expansion, and/or survival of already existing nTreg and iTreg, but inhibits the 
regulatory/suppressive function of these cells by endowing Teff cells resistant to 
suppression by Treg cells. The effect of signaling via 4-1 BB on the generation of iTreg 
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Figure 3. Opposing functions of rapamycin on Treg and Teff cells. Rapamycin inhibits 
the proliferation of activated CD4+ Teff cells through the inhibition of mTOR signaling 
pathway which is crucial for proliferation, transcription, translation, ribosomal synthesis, 
and cytoskeleton organization. Whereas rapamycin facilitates their conversion of 
activated CD4+ Teff cells into iTreg cells without a deleterious effect on the survival and 
expansion of iTreg and nTreg cells. Collectively, these effects result in tilting the balance 




IMMUNOMODULATORY FUNCTION OF SA-4-1BBL ON 
CONVERSION OF NAIVE CD4+ T CELLS INTO CD4+FoxP3+ T 
CELLS 
Introduction 
Despite major breakthroughs in elucidating the effector mechanisms required for 
effective tumor immunity, a number of immune evasion mechanisms employed by 
cancers hinder the successful translation of mechanistic approaches into effective tumor 
immunotherapy. Such evasion mechanisms include the ability of tumors to induce a 
tolerogenic and immunosuppressive microenvironment and secretion of inhibitory factors 
which act synergistically to counteract effector immune responses. One such mechanism 
is the generation and/or preferential recruitment of Treg cells into the tumor or draining 
lymphoid organs. Treg cells playa dominant role in cancer immune evasion mechanisms 
as shown in various clinical (4, 94, 95, 163) as well as preclinical settings (2, 3). Tumors 
modulate immune responses (2, 35, 95) either by recruiting and expanding preexisting 
nTreg cells (164) and/or by converting naive CD4+FoxP3- T cells into iTreg cells (165-
168). These Treg cells then suppress anti-tumor immune responses by targeting cells of 
innate, adaptive, and humoral immunity, such as CD4 and CD8 T lymphocytes, NK cells, 
and B lymphocytes, ultimately leading to tumor progression (164, 169, 170). 
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Although there are various types of T cells with regulatory functions, such as 
CD4+FoxP3- IL-I0 secreting Tr1, CD4-CD8- T cells (171) as well as CD8+ Treg cells 
(172, 173), CD4+FoxP3+ Treg cells appear to play the most dominant role for immune 
regulation under normal physiological as well as disease settings. In humans and rodents, 
Treg cells constitute 5-10% of CD4+ T cell population and can be divided into two 
different types; natural and induced. Although processes involved in the generation of 
nTreg cells in the thymus are well defined, those for iTreg cells are not as extensive but 
include antigen, IL-2, TGF-~ and retinoic acid (67, 174, 175). TGF-~ mediated signals 
are also required for the induction of iTreg cells that are differentiated by antigen from 
naIve CD4 T cells in the periphery. Of critical significance to this study, tumors employ 
some of these molecules for recruitment of nTreg cells or conversion of naIve CD4+ T 
cells into iTreg cells for evading immune surveillance (2, 4, 176). Treg cells exert their 
suppressive function either directly through cell-cell contact or through soluble factor. 
Although the precise mechanism of suppression is still not clear, physical elimination 
(177) and inhibiting IL-2 production (178) needed by effector T cells, induction of 
regulatory DCs (179), inhibition of effector T cell proliferation through TGF-~ (29) and 
IL-IO (180) are some of the mechanisms used by Treg cells for exerting their suppressive 
activity. 
The importance of Treg cells, both nTreg as well as iTreg, in immune evasion 
mechanisms employed by tumors has generated immense interest in efforts to reduce 
number or function of these cells for therapeutic interventions (36, 98). Tumors employ 
multiple mechanisms for evading T cell responses. Some of these include alterations of 
components of the antigen presentation machinery, secretion of inhibitory factors, 
activation of negative regulatory pathways, and recruitment of Treg cell populations (90-
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93). Tumors are known to suppress immunity by promoting the chemokine mediated 
recruitment followed by cytokine mediated expansion, and activation of Treg cells (100). 
This specific recruitment of Treg cells results in the inhibition of effector T cell 
activation, immune escape, and ultimately tumor progression (3). Treg cells represent 
one of the most dominant immune evasion mechanisms employed by tumors for 
progression. Increased numbers of Treg cells in tumor tissue and/or peripheral blood of 
patients with various cancers have been reported (2, 4, 35, 94, 95) and this is associated 
with poor prognosis and survival (2). Dominant role of Treg cells in immune evasion 
mechanisms is evident from various experimental tumor models, where depletion of these 
cells or modulation of their function significantly improved the therapeutic efficacy of the 
vaccines (36, 96-98). Blocking antibodies against some of the signature costimulatory 
molecules expressed by Treg cells like CTLA-4 and GITR were able to induce potent 
antitumor immunity and this was associated with an increased number of tumor-
specific interferon-y-secreting CD4+ and CD8+ T cells in the spleen (98, 99). Strikingly, 
a combination of blocking antibodies against both CTLA-4 and GITR synergistically 
enhanced anti-tumor responses and was able to eradicate more advanced tumors in mice 
(98). 
Interestingly, many tumors are known to produce cytokines such as IL-I0 and 
TGF-~, which promote the proliferation of nTreg cells as well as the conversion of CD4 
T cells into iTreg cells (3, 101, 102). Conversion of naive CD4+ T cells into iTreg 
cells and their accumulation in tumor sites (5, 103) also playa key role in obstructing 
tumor immunosurveillance and cancer immunotherapies (8, 103). In one study, it has 
been reported that cyc100xygenase (COX)-2 and its product prostaglandin, play an 
important role in the pathogenesis of non-small cell lung cancer (104). COX-2 along 
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with its product, prostaglandin, produced by tumors induced the expression of FoxP3 in T 
cells, and consequently increased Treg cell activity in the tumor (105). Furthermore, 
inhibition of COX-2 reduced Treg cell frequency and activity in the tumor and attenuated 
FoxP3 expression in tumor infiltrating lymphocytes along with decreased tumor burden. 
Signaling through TNFR family members play an important role in the activation, 
proliferation, survival, and differentiation of both CD4+ and CD8+ Teff cells (181). 
Among the TNFR family members, 4-1BB has emerged as a key modulator ofCD4+ and 
CD8+ T cell proliferation and survival. 4-1 BB is not constitutively expressed on T cells, 
but rather induced upon T cell activation (182, 183). Signaling through 4-1BB also 
endows T effector cells to be refractory to suppression by Treg cells (Figure 2) (12, 14). 
4-1BB ligation may exert multiple activities on both thymic (nTreg cells) and peripheral 
(iTreg cells) regulatory T cells at several stages. Ligation of 4-1BB promotes the 
proliferation and/or survival of already existing nTreg and iTreg cells, but inhibit the 
regulatory/suppressive function of these cells. However, 4-1BBL activity on the 
conversion of naIve CD4+ T cells to iTreg cells is not known. 
We, therefore, hypothesized that 4-1 BB signaling can be exploited for the 
development of therapeutic vaccines and generated a chimeric molecule, SA-4-1BBL, 
with core streptavidin (SA) where the extracellular domain of the mouse 4-1BBL was 
fused to C-terminus of SA. The SA portion of the molecule allows for oligomerization of 
the chimeric protein that possesses pleiotropic effects on cells of innate, adaptive, and 
regulatory immunity, which translate into therapeutic efficacy against cancer in various 
preclinical settings (184). Importantly, we had previously demonstrated that SA-4-1BBL 
co stimulation makes Teff cells to be refractory to suppression by Treg cells and increases 
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the ratio of CD8+ Teff to Treg cells at the tumor site when used as the adjuvant 
component of tumor associated antigen (TAA) based vaccines (184). Given the 
importance of iTreg cells in tumor immune evasion, we herein tested if SA-4-1BBL 
co stimulation affects the conversion of Teff cells into iTreg cells. Our data demonstrate 
that SA-4-1BBL effectively inhibits antigen- and TGF-~-mediated conversion of Teff 
into Treg cells through induction of IFN-y produced in Teff cells. Importantly, 
immunomodulation with an SA-4-1BBL-based vaccine also blocks the conversion of 
Teff into iTreg cells in a tumor setting in vivo. Collectively, these data demonstrate the 
pleiotropic functions of SA-4-1BBL and its potential as an effective immunomodulator 
for the development of therapeutic vaccines against cancer and chronic infections. 
Materials and Methods 
Mice and reagents 
OVA-specific TCR-transgenic C57BLl6 OT-II (Rag-I) mIce were purchased from 
Taconic Farms. C57BLl6.FoxP3.gfp and C57BLl6 mice were purchased from The 
Jackson Laboratory. OT-II.FoxP3.gfp mIce were generated by crossmg 
C57BLl6.FoxP3.gfp with OT-II (Rag-I-) mice. OT-ILFoxP3.gfp (CD45.1/2) mice were 
generated by crossing C57BLl6.FoxP3.gfp (CD45.2) with OT-ILSJL (CD45.1) mice. 
-1-
C57BLl6 4-1BB mice were kindly provided by Dr. A.T. Vella of University of 
Connecticut, Farmington, CT, with permission from Dr. B.S. Kwon of University of 
Ulsan, Korea. OT-II 4-1BB-1- mice were generated by crossing C57BLl6 4-1BB-1- mice 
with OT-II (Rag-I-). Mice were maintained under specific pathogen-free conditions at the 
University of Louisville (Louisville, KY) and used at the age of 8-10 weeks. This study 
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was reviewed and approved by the Institutional Animal Care and Use Committee of the 
University of Louisville, and animals were cared for in accordance to institutional and 
National Institutes of Health guidelines. OVA peptide (aa 323-339) was purchased from 
AnaSpec, Inc, Fremont, CA. 
CD4+ T cell sorting 
I ·f-Spleen and lymph nodes from OT-II (Rag- -J or OT-II 4-1BB or OT-II.FoxP3.gfp mice 
were harvested and processed into single cell suspension, and RBCs were lysed using 
ACK solution. For sorting CD4+CD2Y T cells from OT-II or OT-II 4-1BB-f - mice, cells 
were stained with CD25-PE and CD4-APC for 30 mins at 4°C. Cells were washed and 
resuspended in HBSS media at a concentration of 5x106/ml in FACS tubes. For sorting 
CD4+FoxP3.gfp- T cells from OT-II.FoxP3.gfp cells were stained with CD4-PE alone for 
30 mins at 4°C. Cells were washed and resuspended in HBSS media at a concentration of 
5 x 106/ml in F ACS tubes. Cells were sorted using a F ACSVantage and F ACSAria cell 
sorters (Figure 4) (BD Biosciences, San Jose, CA). In some experiments, sorted cells 
were labeled with 0.251lM CFSE before using them for in vitro cultures. 
Preparation of APCs 
For the preparation of APCs, spleen and lymph node cells from naIve C57BLl6 mice 
were depleted for T cells by first staining with anti a~-TCR Ab (clone H57 -597) for 30 
mins. Cells were washed and incubated with Low-Tox-M rabbit complement (Cedarlane 
Laboratories, Burlington, NC) for 60 min at 37°C for the lysis of T cells. After several 
washes with PBS, the live cells were irradiated with 2,000 cGy and used as APCs in 
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co culture experiments with sorted OT-II CD4+CD25- T cells or OT-II CD4+FoxP3.gfp- T 
cells. Cells were checked for T cell depletion using flow cytometry (Figure 4). 
In vitro T cell cultures and phenotyping 
5xl05 cells/ml of sorted naive CD4+CD25- T cells from OT-II or OT-II.4-1BB-I- mice or 
CD4+FoxP3.gfp- T cells from OT-II.FoxP3.gfp mice were plated in 96 well plate with 
2xl06 cells/ml ofT cell depleted APCs from C57BLl6 to a final volume of200!J.1. Cells 
were cultured with varying doses of (0.05 - 0.5!J.M) OVA peptide (OVA323-339) and 
cultured in complete MLR media for 4 days. 
Construction, expression, purification and characterization of SA -4-1 BBL is 
previously described (185). To some cultures, SA-4-1BBL (10!J.g/ml) or equimolar 
concentration of SA (2.4!J.g/ml) as control and varying amounts (0 - 2ng/ml) of 
recombinant human TGF-~1 (PeproTech) were also added. Cultured cells were 
phenotyped using CD4 APC (Clone RM4-5) or CD4 PE (Clone GK1.5), CD25 PE or 
CD25 PE-Cy7 (Clone PC61). Intracellular FoxP3 staining was performed to cells that are 
not transgenic for EGFP according to the manufacturer's protocol (eBioscience, San 
Diego, CA). Isotype Abs with matched fluorochromes were used as controls. All 
samples were collected using FACSCalibur or BD LSR II (BD Biosciences) and analyzed 
using FlowJo (Tree Star) or F ACS Diva software respectively. 
For some in vitro experiements, culture supernatants were collected and analyzed 
for cytokines using a BD Cytometric Bead Array (CBA) Mouse Thl/Th2/ThI7 Cytokine 
Kit (BDbiosciences) according to the manufacturer's protocol and analyzed using FCAP 
Array software (Soft Flow, Inc, St. Louis Park, MN). 
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In vivo Tumor experiment 
C57BLl6.SJL (CD45.l) mice were challenged s.c. in the right flank with 3 x 1 06 live 
OVA expressing EG.7 tumor cells. When the tumor size reached 9-10 mm in diameter, 
3-4xl06 sorted CD4+FoxP3.gfp- cells from OT-II.FoxP3.gfp (CD45.1I2) mice were 
adoptively transferred by intratumoral injection (Figure 8a). Mice were vaccinated one 
day later intratumorally with 25 /lg SA-4-1BBL or equimolar SA (control) protein. 
Spleen, draining and non-draining LNs, and tumor were harvested 5 days after 
vaccination and processed into single cell suspension as previously described (184). 
Cells were stained with CD45.l-PE, CD45.2-APC, CD4-Alexa 700 and CD25-PE-Cy7 
and analyzed using flow cytometry. 
Confocal Microscopy for detection of intra-tumor iT reg cells 
Detection of FoxP3.gfp expressed by iTreg cells in the tumor using confocal microscopy 
requires unique tissue processing. During regular tissue processing for confocal 
microscopy, EGFP molecules lose their florescence ability in tissue sections or in cells 
that have lost membrane integrity (186). Therefore, fixation of tumor tissue is required 
before processing. Furthermore, these same fixation procedures must maintain the tissue 
structure so that the ability to detect other cell surface molecules by immunofluorescence. 
Briefly, for tumor confocal microscopy and efficient gfp (FoxP3) green florescence, each 
tumor were dissected into half and before any other procedures, tissues was fixed by 
immersion in 4% paraformaldehyde containing 10% sucrose for 24hrs at room 
temperature (RT) (186). Fixed tissue was embedded in OCT, and snap-frozen above 
liquid nitrogen. Frozen tissue blocks were stored at -70°C and 5 micrometer sections 
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were cut and placed on slides. Slides were dried at R T overnight, and then stained with 
DAPI antibody. Five-micrometer sections were stained with DAPI and analyzed for 
DAPI and gfp (FoxP3) using confocal microscopy. 
Statistical analysis 
Comparisons between two groups were performed using Student's t-test with Microsoft 
Excel software. For each test, P values less than 0.05 considered significant. Data are 
represented as mean ± SD. 
Results 
SA-4-1BBL inhibits antigenic conversion 
NaIve CD4+CD2Y T cells have been shown to convert into iTreg cells under low dose of 
antigenic stimulation (165, 167). The first evidence of in vivo conversion by foreign 
antigens came from a study where mice treated with low doses of antigen cross-linked to 
DEC-205 Ab (targets antigens specifically to DCs) and delivered by osmotic pump. 
Conversion of CD4+CD2Y T cells into iTreg cells was also shown in another adoptive 
transfer model where sorted CD4 cells were transferred into irradiated mice (72). Under 
these lymphophenic conditions, these cells readily underwent conversion and this was 
independent of thymus; but was dependent of CD28 signaling. Similarly, OVA-specific 
naIve T cells from T /B monoclonal mice (17/9 DO 11.1 0 RAG }-I-) converted into 
FoxP3+ iTreg cells when mice were administered with chicken ovalbumin through oral 
route (83). Based on these studies, protocols have been developed for in vitro generation 
of iTreg cells using low doses of a given antigen (187). 
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In vitro generation of iTreg cells reqmres both TCR stimulation and the 
cytokines TGF-~ is absolutely required for naYve CD4+ effector cells to convert into iTreg 
cells. During TCR-stimulation, addition ofTGF-~ to naive CD4+ T cells cultures induces 
the expression of FoxP3 (66). Low dose antigenic conversion is known to depend on 
TGF-~ signaling and conditions that prevent activation of APCs as well as IL-2 
production by naIve T cells (67). Conversion mediated by antigenic stimulation is 
dependent on the accumulation of AP-I signaling molecule that can interact with TCR 
activated NF A T (188). Both AP-l and FoxP3 are known to compete for NF A T binding. 
During subimmunogenic TCR stimulation, lesser availability of AP-l is known to 
facilitate the binding of NF A T to FoxP 3gene locus thereby promoting the expression of 
FoxP3 and generation of iTreg cells (189). Thus, TCR signaling is important in the 
generation of iTreg cells. 
To investigate the effect of SA-4-1 BBL on low dose antigen-driven conversion, 
we cultured naYve CD4+CD2S- T cells transgenic for OV A323-339 with T cell-depleted 
APCs and varying doses of OVA323-339 peptide ranging from O.OS - O.S/lM in the 
presence or absence of exogenous SA-4-1BBL (Figure Sa). After 4 days of culture, 
cultures were stained with CD4-APC, CD2S-PE-Cy7 and FoxP3-PE, and analyzed using 
multiparameter flow cytometry by gating on CD4+ live T cells. There was an antigen 
dose-dependent increase in cell division as assessed by CFSE dilution (Figure Sa). 
Upregulated expression of both CD2S and FoxP3 was seen when sorted naIve CD4+ T 
cells were cultured with lower rather than higher doses of antigen (Figure Sb, upper row). 
Importantly, co stimulation mediated by SA-4-IBBL actively shifts the balance towards 
an effector phenotype which is evident by the decrease in FoxP3+ to FoxP3- ratio (Figure 
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5b, bottom row). Addition of SA control protein did not affect the rate of conversion and 
were comparable to cultures which only received different doses of antigen (Figure 5b, 
middle row). SA-4-1 BBL co stimulation also significantly inhibited the absolute number 
of CD4+ FoxP3.gfp + T cells generated as compared with untreated controls at any given 
dose of antigen (Figure 5d). 
To further test whether this inhibition of conversion is exclusively mediated by 
signaling through 4-1BB ligand, we cultured naIve CD4+CD2Y T cells from OT-II 4-
IBB-1- mice with lowest dose of antigen where the conversion rate was higher. This 
effect was SA-4-1BBL specific and required 4-1BB signaling since 4-1BB KO cells 
treated with SA-4-1BBL had similar levels of FoxP3+ T cells as compared with untreated 
control cells (Figure. 5c). Collectively, these data demonstrate that costimulation 
mediated by SA-4-1BBL antagonizes the low dose antigenic stimulus required for the 
conversion of naIve CD4 + T cells into iTreg cells. 
SA-4-1BBL inhibits TGF-p mediated conversion 
TGF-~ along with TCR stimulation converts peripheral CD4+CD25- naive T cells to 
iTreg cells by induction of transcription factor FoxP3 (69, 166, 167). TGF-~ induces 
FoxP3 expression through the activation of the transcription factor SMAD3 which in 
combination with TCR induced NFAT binds to the enhancer region of FoxP3 ultimately 
resulting in its transcription (132). The findings that 4-1 BB stimulation under low dose 
of antigen appeared to inhibit the conversion of CD4 T cells into FoxP3 expressing Treg 
cells prompted us to further investigate the activity of 4-1 BB signaling on TGF-~ 
mediated iTreg generation. To this purpose we used a higher dose of antigen where we 
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do not see the effect of antigen driven conversion (Figure Sa). Stimulating naIve CD4+ 
FoxP3.gfp- T cells at higher dose of antigen (O.SIlM) in the presence of exogenous TGF-~ 
resulted in FoxP3+ iTreg cells in a dose dependent manner (Figure 6a, upper row). A 
blocking Ab to TGF -~ totally blocked the generation of iTreg cells, demonstrating the 
specificity of TGF -~-mediated conversion (Figure 6b). Consistent with the low-dose 
antigenic stimulation, SA-4-1 BBL costimulation significantly inhibited the TGF-~­
mediated conversion as assessed by percent as well as absolute number of CD4+ 
FoxP3.gfp+ T cells generated as compared with SA treated or untreated controls (Figure 
6a, b). Collectively, these results demonstrate that signaling through 4-1 BB on activated 
T cells can suppress the expression of FoxP3 in the presence of exogenous TGF-~. 
Cytokine milieu established by 4-1BB signaling control the conversion 
It has been demonstrated by various studies that signaling through OX40, another TNFR 
family costimulatory member, results in the inhibition of both low dose antigen as well as 
TGF-~ mediated conversion of naIve CD4+CD2Y T cells into iTreg cells (190,191). One 
study showed that signaling through OX40 induces memory T cells and IFN-y produced 
by these memory T cells inhibit TGF-~ mediated conversion of naIve CD4+T cells into 
iTreg cell (192). In a different model, another study has shown that OX40 induced IFN-
y, IL-6 and IL-4 block the generation of iTreg cells from naIve CD4+ T cells 
During T cell activation signaling through 4-1 BB is shown to promote the 
secretion of differentiating cytokines such as IFN -y and IL-4 (181), but the role of these 
cytokines in the generation of iTreg cells is not clear. We analyzed the culture 
supernatants for various Thl/Th2/Th17 cytokines using cytometric bead array. It 
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revealed that 4-1 BB stimulation significantly increased the production of IFN -y but not 
IL-4, IL-6 and IL-17 (Figure 7a). To determine to what extent these cytokines playa role 
in SA-4-1BBL mediated inhibition of Treg conversion, blocking Abs against IFN-y and 
IL-4 at varying doses were added to the cultures containing TGF-~ and SA-4-1BBL. 
Addition of 5!!g/ml of a-IFN-y Ab to cultures stimulated with SA-4-1BBL partially 
rescued the conversion of naIve CD4 T cells into Treg cells mediated by TGF-~ (Figure 
7b). Importantly, addition of 25!!g/ml a-IFN-y Ab to the cultures significantly increased 
the frequency of FoxP3+ T cells completely abolishing the effect of 4-1BBL as shown by 
the percentage as well as the absolute number of CD4+FoxP3.gfp + T cells (Figure 7b, c). 
We could not totally rescue the absolute number of CD4+FoxP3.gfp+ T cells by adding 
25!!g/ml a-IFN-y Ab as compared to TGF-~ alone (Figure 7c), which might be due to 
secondary effects of blocking a-IFN-y Ab. We saw a decreased live cells (data not 
shown) when we added antibodies to the cultures. Due to this decreased live cells in the 
cultures, we compared the ratios of Teff cells versus iTreg cells and found that SA-4-
IBBL decreased the absolute number of CD4+FoxP3+ cells as compared to CD4+FoxP3-
cells and this effect was reverted when we added 25!!g of IFN-y to the cultures (Figure 
7d). Consistent with our cytokine quantitative data (Figure 7a), addition of a-IL-4 Ab to 
cultures stimulated with SA-4-1BBL had no effect on the conversion of naIve CD4 T 
cells into Treg cells (Figure 7b, c). Collectively, these results indicate that IFN-y 
stimulated by 4-1BB signaling playa major role in inhibiting TGF-ji mediated Treg 
converslOn. 
SA-4-1BBL inhibits tumor mediated conversion 
Treg cells, both naturally occurring and induced, playa dominant role in tumor immune 
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evasion mechanisms as demonstrated by a series of clinic (193) and preclinical studies 
(164, 168, 194). Importantly, most tumors express high levels ofTGF-~, and as such can 
actively convert tumor-specific T effector cells into iTreg cells as an effective means of 
immune evasion (195). We, therefore, tested if the observed immunomodulatory effect 
ofSA-4-1BBL on iTreg conversion can be translated in vivo in the OVA expressing EG.7 
tumor model (Figure 8a). In this context, we first determined whether established EG.7 
OVA tumors can convert adoptively transferred naIve CD4+FoxP3.gfp- cells from OT-
II.FoxP3.gfp mice into CD4+FoxP3.gfp + cells. As expected, control SA injected mice 
converted CD4+FoxP3.gfp- cells into CD4+FoxP3.gfp + cells significantly in spleen 
(Figure 8b) and to a lesser extent in the draining LN (dLN) (Figure 8c). Similar to the in 
vitro data, mice vaccinated with SA-4-1BBL readily blocked the tumor mediated 
conversion as evident by the decrease in the percentage of CD4+FoxP3.gfp+ cells in 
spleen and dLN (Figure 8b, c). Although, we observed high levels of iTreg cells in tumor 
draining LNs as compared with SA-treated controls, this difference did not reach 
statistical significance. This effect was also seen within the tumor microenvironment as 
significantly lower number of FoxP3.gfp+ cells were evident in tumors of mice vaccinated 
with SA-4-1BBL as compared to SA control tumors (Figure 9a, b). Confocal microscopy 
further showed that SA-4-1BBL blocks the accumulation of FoxP3.gfp+ T cells in the 
tumor as compared to SA control tumors. Taken together, these results demonstrate that 
immunomodulation with SA-4-1BBL is effective in preventing the conversion of 
CD4+FoxP3.gfp- T effector cells into CD4+FoxP3.gfp+ iTreg cells in a tumor 
microenvironment. These results are consistent with and provide a plausible mechanistic 
insight into our recently published studies demonstrating that vaccination with SA-4-
1 BBL and HPV E7 T AA showed potent therapeutic efficacy established TC-l tumors 
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that was associated with the production of high levels of IFN-y and a higher intratumoral 
CD8+ Teff/Treg ratio (196). 
Discussion 
Signaling through 4-1 BB receptor plays a critical role in modulating not only 
adaptive, but also innate and regulatory immunity as demonstrated by us (184, 185) and 
others (197-200), and as such may have important therapeutic implications in settings of 
autoimmunity, cancer, and chronic infections. In the context of regulatory immunity, 
signaling via 4-1BB receptor may have diverse and opposing consequences. For 
example, we (185) and others (199, 200) have previously demonstrated that signaling via 
4-1 BB on naturally occurring Treg cells serves to expand them in vitro in the presence of 
exogenous IL-2. However, Treg cells have no suppressive function in the presence of the 
ligand since signaling via 4-1 BB on T effector cells endows these cells to be refractory to 
inhibition by Treg cells (185) via yet to be defined mechanisms. Although, the 
physiological consequence of the expansion of nTreg cells via 4-1 BB signaling during 
the course of an immune response is not obvious, it may serve as an alternative 
mechanism to activation induced cell death for achieving immune homeostasis after an 
antigenic challenge andlor preventing extensive collateral damage by controlling the 
function of expanded Teff cells. This outcome may be regulated by transient interaction 
between 4-1BBL inducible expressed on APCs with 4-1BB on Treg and Teff cells. The 
present study reveals another important and novel function of 4-1 BB signaling on 
regulating the balance between adaptive and regulatory immunity, i.e., blocking the de 
novo generation of iTreg cells from Teff cells through IFN-y production. Therefore, the 
triple function of 4-1 BB signaling on T cells to i) enhance activation of naIve T cells, 
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survival, and differentiation into long-term memory with a Thl response (184) ii) endow 
Teff cells to be refractory to inhibition by Treg cells (185), and iii) inhibit the conversion 
of Teff cells to iTreg cells, reported in the present study, may have important implications 
for the treatment of cancer that exploits Treg cells for immune evasion (164, 170) and 
requires a Th 1 dominated response for immunotherapy (196). These features are not 
unique to 4-1BB as OX-40, another member of the TNFR superfamily, has similar effects 
in regulating the balance between Teff and Treg cells with the exception that it directly 
blocks the inhibitory function of Treg cells via the down regulation of FoxP3 expression 
(201, 202). Similar to our finding with 4-1BB, OX-40 also utilizes IFN-y to block the 
conversion of Teff cells into iTreg cells (190,191,203) even though there are reports that 
OX-40 induced IL-4 and IFN-y (190) or in combination with IL-6 (203) are required for 
this function. The likely cause for such a discrepancy can be attributed to different 
culture systems used. Given the preferential effect of signaling via OX-40 on CD4+ and 
4-1 BB on CD8+ T cell function (204) and the importance of both of these cell types for 
the generation of effective immune responses, a combinatorial use of agonists for these 
two receptors for immunomodulation bears significant therapeutic potential for cancer 
and chronic infections. 
4-1BB signaling is known to promote cell division, survival, and cytokine 
production. The downstream molecules and their transcribed products that are 
upregulated by 4-1BB signaling might negatively regulate transcription of FoxP3 that is 
mediated by TGF-~ signaling. Current study indicate that cytokines such as IFN-y 
produced from 4-1BB signaling may be important for suppressing FoxP3 expression, 
essentially providing a mechanism for suppressing iTreg cell generation. The source of 
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IFN-y produced in these cultures is mainly from sorted naive CD4+ cells stimulated with 
antigen, but not from APCs as we did not detect any IFN-y in the culture supernatants 
containing APCs alone (data not shown). This suggests that increased IFN-y produced by 
SA-4-1BBL stimulated CD4+ cells acts in an autocrine fashion serving as an inhibitor of 
FoxP3 expression. 
It is presently unknown how IFN-y produced by 4-IBB signaling might interfere 
with the induction ofFoxP3 in antigen-stimulated naIve T cells. IFN-y might act either 
directly or indirectly on multiple signaling pathways that are required for the FoxP3 
expression. First, naIve CD4 T cells give rise to Thl, Th2, Th17, and iTreg populations, 
mainly promoted in a cytokine-dependent manner which in tum regulates various 
lineage-specific transcription factors like T-bet, GATA-3, RORyt, and FoxP3, 
respectively (205). Interestingly, recent data found that Th 1 and Th2 lineage-specific 
cytokines like IFN-y, IL-12 and IL-4 and the transcription factors they upregulate (T-bet 
by IFN-y and IL-12; GATA-3 by IL-4), act as strong suppressors of FoxP3 
expression (206). Thus, it is possible that IFN-y induced by 4-1BB signaling might 
indirectly promote to upregulation of T-bet. T-bet may in tum suppress TGF-~ mediated 
transcription ofFoxP3. Second, prolonged TGF-~ receptor signaling is necessary to 
maintain intracellular FoxP3 (79, 207), which might be due to the requirement for DNA 
demethylation and epigenetic modification at the FoxP3 promoter site. This suggests that 
upstream or downstream signals from the TGF-~ signaling like SMAD3, might be the 
primary targets of suppression by IFN-y signaling pathway. Third, it has been recently 
shown that TGF -~ signaling was found to promote upstream demethylation of 
the FoxP3 gene, thereby enhancing FoxP3 expression. Even though the exact mechanism 
of this process is unknown, it is speculated that this might be mediated by TGF-~ 
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signaling mediated suppression of a DNA methyltransferase (208). Inhibiting the TGF-~ 
mediated suppression of DNA methyltransferase might also serve as an alternate target 
for INF-y antagonism on FoxP3 expression. 
In conclusion, previous studies have shown that signaling via 4-1BB on nTreg 
cells can expand them in vitro (12, 162,209) as well as endows Teff cells to be refractory 
to inhibition by Treg cells (185). In the current study, we have shown that 4-1BB 
signaling also inhibit the conversion of Teff cells to iTreg cells through the production of 
INF-y. Although, the physiological consequence of these contradicting functions of 4-
1BB signaling during the course of an immune response is not obvious, it may serve in 
achieving immune homeostasis. 4-1BB signaling on Teff cells might help in mounting 
an effective immune response to pathogens while simultaneously expanding Treg cells. 
Once pathogen is cleared, the expanded Treg cells can then regulate the function of Teff 
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Figure 4. Outline of in vitro conversion of naIve CD4+ T cells into FoxP3+ T cells. 
Briefly, sorted CD4+CD2Yor CD4+FoxP3.gfp- cells were cultured with T cell depleted 
APCs in the presence of OVA323-339 peptide (0.05 to 0.75IlM), TGF-~ (0.1 to 2ng/ml), 
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Figure 5. 4-1BBL inhibits the conversion of naIve CD4 T cells into CD25+PoxP3+ T 
cells. A, In vitro CD4+ T cell CPSE cell division. Flow sorted CD4+ T cells were 
stimulated for 4 days with various doses of OV A323-339 peptide in the presence of 
irradiated C57BL!6 T cell depleted APCs. CFSE dilution was analyzed using flow 
cytometry by gating on CD4+ cells. B, naIve CD4+ CD2Y T cells from wild type OT-II 
transgenic mice were cultured with APCs (T cell depleted) and with various doses of 
OVA323-339 peptide (upper row) in the presence of SA- 4-1BBL (bottom row) and 
equimolar SA (middle row) as control. After 4 days, CD25 and intracellular FoxP3 were 
evaluated by gating on CD4+ T cell population using flow cytometry. Data is 
representative of at least three independent experiments. C, as in B, naIve CD4+ CD2S-
T cells from 4-1 BB"/- OT -II transgenic mice were cultured with O.05IlM of OV A323-339 
peptide with (bottom row) or without (upper row) SA- 4-1 BBL and FoxP3 and CD25 
expression was accessed by gating on CD4+ T cells. D, Absolute number of CD4+PoxP3+ 
T cells generated from cultures as in B. Data is representative of at least three 
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Figure 6. 4-IBBL suppresses expression of FoxP3 induced by exogenous TGF-~. A, 
naIve CD4+FoxP3.gfp- T cells from OT-II.FoxP3.gfp mice were cultured with T cell 
depleted APCs and O.5~M OVA323-339 with different doses of exogenous TGF-~ in the 
presence (lower row) or absence (upper row) of SA-4-IBBL or with equimolar 
concentration of SA (middle row) as control. At day 4, CD25 and EGFP (FoxP3) 
expression in CD4+ T cells was analyzed using flow cytometry. Data is representative of 
at least three experiments. B, C, as in A were cultured and analyzed after 4 days of 
stimulation for total number (B) or percentage (C) of live CD4+FoxP3.gfp+ cells 
generated. a-TGF-~ neutralizing antibody was used as control. Data are mean ± SD and 
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Figure 7. 4-1BBL suppression of FoxP3 induction is mediated by IFN-y. A, naIve 
CD4+FoxP3.gfp' T cells from OT-II.FoxP3.gfp mice were cultured with T cell depleted 
APCs and O.5)lM OVA323-339 with exogenous TGF-~ (2ng/ml) with or without 4-1BBL 
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(lOllg/ml) and 4 days later, culture supernatants were analyzed for levels of various 
cytokines. B, as in A, naIve CD4+FoxP3.gfp- T cells from OT-ILFoxP3.gfp mice were 
cultured in the presence or absence of varying doses of IFN -y or IL-4 blocking 
antibodies. At day 4, CD25 and EGFP (FoxP3) expression in CD4 T cells was analyzed 
using flow cytometry. C, absolute number ofCD4+FoxP3.gfp+ T cells from B. D, ratio of 
the absolute number of CD4+FoxP3.gfp- cells versus CD4+FoxP3.gfp+ from the cultures 
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Figure 8. SA-4-1BBL blocks the accumulation ofCD4+FoxP3.gfp+ T cells in spleen and 
dLN. A. Schematic diagram of in vivo tumor experiment. B, C, sorted naIve 
CD4+FoxP3.gfp- T cells (CD45.1I2+; 4 x 106) were injected intratumorally into tumor 
bearing C57BLl6.SJL (CD45.1 +) mice. On the next day, mice were vaccinated 
intratumorally with SA-4-IBBL (25 /lg) or equimolar SA control protein. Transferred 
cells were assessed from spleen (B) and draining LNs (C) 5 d after vaccination by gating 
on CD4+CD45.112+ cells using flow cytometry. Data are mean ± SD and are 
representative of two independent experiments with at least 3 animals per group. 
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Figure 9. SA-4-1BBL blocks the accumulation of CD4+FoxP3.gfp+ T cells within the 
tumor. A, confocal microscopic images of tumor tissue showing intracellular gfp 
(FoxP3, green) and DAPI (blue). B, absolute number of cells from more than three areas 
per donor sample from three independent donor samples per group counted from the 
confocal images. Control tumors did ·not receive CD4+FoxP3.gfp- cells and served as a 
background for gfp (FoxP3) staining. 
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CHAPTER 3 
IMMUNOMODULATORY FUNCTION OF SA-4-1BBL AND 
RAPAMYCIN ON iTreg CELL GENERATION 
Introduction 
Allogeneic transplantation rejection is associated with activation and proliferation 
of effector cells that, along with the release of proinflammatory cytokines, result in tissue 
damage (106). The activities of Treg cells are now recognized as fundamental to the 
development and maintenance of immune tolerance and shown to inhibit alloreactive T-
cell activation and effector cell function (6, 115) serving as an attractive therapeutic tool 
for inducing tolerance (116, 117). Numerous reports targeting Treg cells showed that by 
manipulating the numbers and/or function of Treg cells can decrease pathology in a wide 
range of contexts, such as autoimmunity and transplantation in preclinical models. 
Allogeneic graft rejection is initiated and perpetuated primarily by T cells that 
respond to allogeneic MHC molecules via direct and indirect recognition pathways (210). 
The importance of T cells in allograft rejection is demonstrated by the acceptance of 
allogeneic grafts by nude mice primarily deficient in T cells. Furthermore, most of the 
immunosuppressive drugs used in clinical transplantation to control graft rejection are 
targeted at T cells. After recognition of allogeneic antigens via TCR, T cells get 
activated, proliferate, expand, and acquire effector functions that not only directly inflict 
damage to the graft but also initiate a senes of other effector mechanisms, such as 
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proinflammatory and humoral, that ultimately results in the destruction of the graft. 
Therefore, various immunosuppressive drugs have been developed that target various 
aspects of T cells activation and effector functions for the control of graft rejection. Most 
protocols use a combination of agents in a chronic fashion to achieve this goal. Although 
successful in preventing allograft rejection, the chronic use of these non-specific 
immunosuppressive drugs not only has direct toxic effects on the host and the graft, but 
also increases the risk of opportunistic infections and cancer due to a compromised 
Immune response. Therefore, the ultimate goal of the transplantation field is to develop 
tolerogenic regimens that prevent graft rejection in the absence of immunosuppression 
while preserving immunocompetence. Although many current transplantation protocols 
require the use of immunosuppressive agents that targets calcineurin and mTOR 
pathways, a preference is developing towards specifically targeting the mTOR pathway 
for not merely the control of acute rejection, but also induction of tolerance in 
combination with regimens that are designed to achieve this goal. In this context, 
rapamycin emerged as the drug of choice. 
Unlike other immunosuppressive agents that are designed to suppress Teff cells, 
rapamycin has several advantages as it not only effectively suppress Teff cells by 
arresting them in the cell cycle (211), but also facilitate the conversion of these cells into 
iTreg cells (120), (127). In addition, rapamycin does not negatively affect the activation 
and proliferation of nTreg cells. Importantly, rapamycin has been shown to change the 
behavior of DCs into a tolerogenic one. Collectively, these pleiotropic effects of 
rapamycin have the potential to induce tolerance in the absence of continuous use of 
nonspecific generalized immunosuppression. A series of studies have provided direct 
evidence for the pleiotropic effects of rapamycin on immune responses in preclinical and 
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clinical settings. Inhibition of mTOR activity in mice causes marked decrease in T cell 
proportion in the periphery (211). Extended use of rapamycin administration blocks the 
conversion of thymocytes from double-negative (CD4-CD8-) to double-positive (CD4+ 
CD8+) T cells in the thymus (212), thereby interfering with the development of Teff cells 
and potentially nTreg cells. Although rapamycin decreases the absolute number of T 
cells in the periphery, it does not alter the proportion of CD4+FoxP3+ Treg cells in the 
periphery (127). This indicates that the nTreg cell population is unaffected by mTOR 
blockade mediated by rapamycin. Recent evidence suggests that FoxP3 expression in T 
cells is negatively regulated by the PI3K-AKT-mTOR pathway, which is shown by the 
blockade of FoxP3 upregulation in the presence of constitutive AKT activation (213). 
This suggest that rapamycin mediated blockade of mTOR will yield higher proportion of 
CD4+ cells that have upregulated expression ofFoxP3. 
Treg cell function and homeostasis are not affected by rapamycin as compared to 
its effect on Teff cells. Mouse or human Treg cells exposed to rapamycin in vitro have 
normal suppressive function on Teff cell proliferation (128). This is not the case when 
other immunosuppressive agents, such as calcineurin inhibitor cyclosporin A, are used 
(214, 215). In addition, extended administration of rapamycin in vivo results in a 
decrease in the absolute numbers of all T cells in face of an increase in the number of 
Treg cells (127, 129,215). These preclinical observations also apply to clinical settings 
as it was shown that patients who received kidney transplants when treated with 
rapamycin have a marked increase in the frequency of Treg cells as compared with total 
CD4+ T cell numbers (129, 216). 
TGF-~ converts CD4+CD2Y T cells into FoxP3 expressmg iTreg cells in the 
presence ofTCR stimulation and IL-2 (217). The observation that both TGF-~ and 
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rapamycin mediate the expression of FoxP3 in T cells led to investigations focused on 
common signaling pathways involved, especially the mTOR pathway. The induction of 
FoxP3 transcription by TGF-~ depends on the activation of the transcription factor 
SMAD3, which in combination with TCR signal activated NF AT , binds to the enhancer 
region of FoxP3 and initiate the transcription of this gene (132). T cells that are not 
treated with rapamycin, signaling through the mTOR pathway can inhibit the activation 
of SMAD3, thereby downregulating the expression of FoxP3 (133). The blockade of 
mTOR pathway by rapamycin leads to the activation ofSMAD3 that in tum binds FoxP3 
gene, upregulate its expression, and thereby converting Teff cells into iTreg cells. These 
aspects of rapamycin, therefore, qualify this drug as immunomodulatory component of 
therapeutic approaches targeting the induction of transplantation tolerance. For example, 
by using rapamycin in conjunction with blocking antibodies against CXC-chemokine 
receptor 3 (CXCR3) and its ligands (CXCL9, CXCLIO and CXCLll) that are important 
for effector T cell recruitment, increased the survival rate of islet as well as heart allograft 
(218). 
The synergetic activity of rapamycin with signal 3, i.e. IL-2 or TGF-~, in 
expanding Treg cells or converting Teff cells into iTreg cells, suggests that rapamycin 
may be used in combination with signal 2 agents, such as costimulatory molecules of 
TNF family, to change the Teff:Treg balance in favor of Treg cells for the induction of 
transplantation tolerance. TNFR costimulatory molecules play an important role in 
regulating innate, adoptive and regulatory arms of the immune system. Costimulatory 
receptor 4-1 BB is constitutively expressed on Treg cells and ligation of 4-1 BB is 
effective in expanding these cells without loss oftheir immunosuppressive function (162, 
209). The 4-1BB expression on Treg cells may be advantageous for increasing their 
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expansion or survival in the context of transplantation, provided that the positive impact 
of this signaling on Teff cells is simultaneously inhibited. In this context, rapamycin as 
an immunosuppressive drug known to preferentially block the cycling of Teff cells 
without a negative effect on Treg cells generation, proliferation, and effector function 
emerges as the immunosuppressive drug of choice (127, 128, 130,219). Importantly, the 
positive effect of rapamycin on the conversion of conventional CD4+ T Cells into iTreg 
cells under TCR stimulation without impairment of their potent immunosuppressive 
activity (131, 220), provides additional incentive as the drug of choice and justifies the 
combinatorial use of 4-1 BBL and rapamycin for the induction of tolerance. 
We, therefore, conducted a series of in vitro studies as a prelude to in vivo 
tolerance induction efforts to test if 4-1BB co stimulation works in synergy with 
rapamycin TCR stimulation and IL-2 to block the proliferative function of Teff cells and 
convert these cells into iTreg cells. Our data demonstrate that 4-1 BBL stimulation 
induces the proliferation of Teff cells and rapamycin effectively block this proliferation 
for the generation of iTreg cells. 
Material and Methods 
Mice and reagents 
C57BLl6 and BALB/c mice were purchased from Jackson Laboratories or bred in our 
animal facility. Mice were maintained under specific pathogen-free conditions at the 
University of Louisville (Louisville, KY) and used at the age of 8-10 weeks. This study 
was reviewed and approved by the Institutional Animal Care and Use Committee of the 
University of Louisville, and animals were cared for in accordance to institutional and 
National Institutes of Health guidelines. 
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+ ~ CD4 T cell sorting from C57BL/6 or C57BL/6 4-1BB mice 
-/-
Spleen and lymph nodes from C57BLl6 or C57BLl6 4-1 BB mice were harvested and 
processed into single cell suspension, and RBCs were lysed using ACK solution. For 
CD4 cell sorting, cells were stained with CD25-PE, and CD4-APC. NaIve CD4+CD25- T 
cells were sorted using a F ACSVantage and F ACSAria cell sorters (BD Biosciences). 
Sorted cells were >95% pure. 
Preparation of APCs from BALB/c 
For the preparation of APCs, spleen and lymph node cells from naIve BALB/c mice were 
depleted for T cells by first staining with anti ap-TCR Ab (clone H57 -597) for 30 mins. 
Cells were washed and incubated with Low-Tox-M rabbit complement (Cedarlane 
Laboratories, Burlington, NC) for 60 min at 37°C for the lysis of T cells. After several 
washes with PBS, the live cells were irradiated with 2,000 cGy and used as APCs in 
-/- + 
coculture experiments with sorted C57BLl6 or C57BLl6 4-1BB CD4 T cells. Cells 
were checked for T cell depletion using flow cytometry (Figure 4). 
In vitro T cell cultures and phenotyping 
5xl05 cells/ml of sorted naIve CD4+CD2Y T cells from C57BLl6 or C57BLl6 4-1BB-/-
mice were plated with 2 x 106 cells/ml of T cell depleted APCs from BALB/c in the 
presence of varying concentration of rapamycin and cultured in complete MLR media for 
4 days. SA-4-1BBL (lOllg/ml) or equimolar concentration of SA (2.4llg/ml) as control 
and rIL-2 were also added to the cultures. Cultured cells were phenopyped using CD4 
APC (Clone RM4-5) or CD4 PE (Clone GKl.5), CD25 PE or CD25 PE-Cy7 (Clone 
PC6l). IntracellularFoxP3 staining was performed according to the manufacturer's 
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protocol (eBioscience). Isotype Abs with matched fluorochromes were used as controls. 
All samples were collected using FACSCalibur or BD LSR II (BD Biosciences) and 
analyzed using FlowJo (Tree Star) or F ACS Diva software respectively. 
Results 
Rapamycin and IL-2 work in synergy to generate iTreg cells from alloreactive 
CD4+ Teff cells 
Given that IL-2 is required for the generation of iTreg cells, we first assessed the ability 
of various doses of rapamycin in combination with IL-2 on the growth and differentiation 
of naive CD4+ T cells and their conversion into iTreg cells in an allogeneic setting. To 
this purpose, sorted CD4+ T cells were stimulated with irradiated allogeneic APCs in the 
presence or absence of IL-2 and varying doses of rapamycin. Under normal allogeneic 
setting or in the presence of rapamycin, irrespective of its dose, we did not observe 
enhancement of the generation of CD25+FoxP3+ iTreg cells (Figure 10). In marked 
contrast, rapamycin significantly increased the percentage of CD25+FoxP3+ Treg cells in 
the presence of IL-2 (Figure 10). However, Treg proportions were reduced by higher 
dose of rapamycin (Figure 10). In conclusion, adding lower dose of rapamycin in the 
presence of IL-2 was advantageous in increasing the overall nwnber of CD25+FoxP3+ 
iTreg cells. 
4-1BBL in the presence of IL-2 and rapamycin further increases the generation of 
CD2S+FoxP3+ iTreg cells from Teff cells 
Since the IL-2 and low dose of rapamycin preferentially generated iTreg cells and these 
cells express 4-1BB receptor, we next tested if costimulation with SA-4-1BBL further 
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Improves the efficacy of this regImen In further generating/expanding iTreg cells. 
Addition of SA-4-1BBL alone without IL-2 to allogeneic cultures in the presence of 
rapamycin significantly increased the proportion of iTreg cells in these cultures (Figure 
11). More importantly, the combination of 4-1BBL, IL-2, and rapamycin had the most 
potent effect on the generation/expansion of iTreg cells (Figure 11). We also noticed that 
addition of rapamycin to the cultures significantly reduced the percentage of 
CD4+FoxP3+ T cells expressing CD25, indicating that rapamycin preferentially blocks the 
proliferation of allogeneic CD4+ effector cells (Figure 11). Taken together, these data 
demonstrate that the provision of three signals (allogeneic TCR stimulation, 4-1 BBL 
mediated co-stimulation, and IL-2 cytokine) in the presence of rapamycin is an effective 
and clinically applicable approach that effectively increases the generation/expansion of 
iTreg cells. 
4-1BB, but not CD28 signaling, is crucial for rapamycin mediated increase in the 
generation/expansion of iTreg cells 
Co stimulation via CD28 is critical for the generation ofnTreg cells. We, therefore, tested 
if this costimulatory signal also has similar effects on the generation of iTreg cells in the 
presence of rapamycin and how this effect compares with 4-1BB costimulation. To 
compare the ability of CD28 versus 4-1 BB co stimulation to increase the rapamycin/IL-2-
mediated generation of iTreg cells, we added anti-CD28 stimulating antibody to the 
cultures containing rapamycin and IL-2. To our surprise, CD28 costimulation was not 
able to enhance the generation of iTreg cells in the cultures containing rapamycin and IL-
2 (Figure 12). This data suggest that only 4-1 BB, but not CD28, signaling is efficacious 
in generating iTreg cells in synergy with rapamycin and IL-2. 
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Discussion 
When we cultured naIve CD4+ T cells in an allogeneic setting in the presence of 
rapamycin, we observed two major effects. First, in order for rapamycin to convert these 
cells into CD25+FoxP3+ iTreg cells, IL-2 is absolutely required. Rapamycin through 
mTOR inhibition is thought to skew towards the conversion of CD4+ T cells into iTreg by 
increased usage of the STAT5 pathway over the PI3K pathway in response to IL-2 (221) 
and in tum IL-2 receptor dependent STA T5 activation is required for FoxP3 transcription 
(222). Thus, the rapamycin mediated mTOR inhibition in the presence of IL-2 signaling 
favors the conversion/expansion of iTreg cells. 
The second effect of rapamycm IS decrease in the proliferation of these 
CD4+FoxP3- T cells which correlates with decreased number of cells expressing CD25. 
The addition of rapamycin to the expansion culture was required for outgrowth of 
converted iTreg cells at the expense of Teff cells. 
Prior reports indicated that 4-1 BB signaling can expand Treg cells without losing 
their suppressive activity (12). Our data clearly demonstrate that in the absence of 
rapamycin, signaling through 4-1BB actually promoted the proliferation of CD4+FoxP3-
T cells. This is consistent with the previous studies showing that signaling through 4-
1BB promotes the proliferation, survival and function of effector CD4+ and CD8+ T cells 
(12, 140). Importantly, 4-1 BB signaling in the presence of rapamycin and IL-2 clearly 
increased the rapamycin converted iTreg cell as we observed higher percentage of cells 
expressing FoxP3 when cultures were added SA-4-1BBL along with rapamycin and IL-2 
as compared to rapamycin or rapamycin and IL-2 cultures. 
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It has been recently reported that CD28 signaling plays a crucial role in the 
development of Treg cells (9, 48) and these cells can be expanded in vitro using TCR and 
CD28 stimulation (223). Moreover, CD28 signaling acts earlier than 4-1 BB due to its 
constitutive expression on naive CD4 T cells. We compared the ability of CD28 
signaling to 4-1BB in expanding the rapamycin converted iTreg cells. We observed that 
4-IBB but not CD28 co stimulation is effective in increasing the CD2S+FoxP3+ T cell 
proportion in the cultures. This suggests that 4-1 BB delivers quantitatively or 
qualitatively different signals as compared to CD28 that allow expansion of rapamycin 
and IL-2 mediated iTreg cells. 
The observed difference between 4-1 BB and CD28 signaling might be due to 
differential expression kinetics and signaling pathways used by these costimulatory 
molecules. During conventional T cell activation, mTOR signaling integrates the TCR 
and CD28 signals to transit from GO to G 1 phase of the cell cycle which requires 
activation of NFAT (TCR induced), mitogen-activated protein kinases (MAPKs), API 
(CD28 induced) and nuclear factor-KB (NF-KB) (224). The coordinated activity of these 
factors determines the expression of many genes that are involved in cell cycle 
progression along with the expression of IL-2 and IL-2 receptor. Whereas, 4-1 BB 
signaling in the presence of TCR signal leads to activation of JUN N-terminal kinase 
(JNK), API, MAPKs, ERK, NF-KB and NFAT. These molecules are involved in 
promoting the production of IL-2, IL-4, IL-S and IFN-y. Costimulation through both 
CD28 as well as 4-1BB results in the production of IL-2 and signaling through IL-2 
receptor in tum activates mTOR through the PI3K-AKT-mediated signaling pathway 
which ultimately lead to G 1 to S phase progression. So, both costimulatory molecules 
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indirectly use the mTOR pathway for promoting cell cycling. In the current study, we 
block the mTOR pathway using rapamycin, but still see an increase in the FoxP3 iTreg 
cells when we add SA-4-1BBL but not a-CD28 activating antibody. The reason for this 
observed discrepancy might be due to other signaling pathways that might be involved or 
used by 4-1BB signaling in promoting the expression of FoxP3. Another reason for this 
differential effect of CD28 and 4-1 BB signaling might lie in the expression kinetics of 
CD28 and 4-1 BB. CD28 and 4-1 BB are expressed at various time points during the 
activation of T cells. CD28 is constitutively expressed on T cells and acts initially during 
the T cell activation. Whereas, 4-1 BB is expressed later after T cell and CD28 
stimulation, and is only induced on T cells after activation. Further signaling studies on 
these two costimulatory molecules and the factors they recruit will shed more light on the 
differential effects we have observed in this study. 
In conclusion, we have shown that low dose of rapamycin in the presence of IL-2 
signaling promotes the conversion of naIve CD4+ T cells into iTreg cells. 4-1 BB 
signaling further promotes the expansion of iTreg cells in a synergistic manner. 
Furthermore, CD28 signaling did not promote the expansion of iTreg cells in contrast to 
4-1 BB signaling. These data not only have important implications for inducing Treg cells 
in transplantation setting, but also provide novel insights into the biologic effects of 4-
1 BBL on Treg cell expansion. 
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Figure 10. Lower dose ofrapamycin in the presence ofIL-2 is effective in increasing the 
CD25+FoxP3+ T cell proportion. NaIve CD4+ CD2Y T cells from C57BLl6 mice were 
cultured with BALB/c APCs (T cell depleted) and with various doses of rapamycin (1 
nM and 10 nM) in the presence or absence of IL-2 (25 U/ml). After 4 days, cells were 
evaluated for CD25 and intracellular FoxP3 by gating on CD4 population using flow 
cytometry. Data is representative of at least two independent experiments. 
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Figure 11. Synergy between SA-4-1BBL and IL-2 in increasing the CD25+PoxP3+ T 
cell proportion in the presence of low dose of rapamycin. NaIve CD4+ CD25- T cells 
from C57BLl6 mice were cultured with BALB/c APCs (T cell depleted) and with or 
without rapamycin (l nM) in the presence or absence oflL-2 (25 U/ml), and SA-4-1BBL 
(lO )lg/ml) or in combination. After 4 days, cells were evaluated for CD25 and 
intracellular FoxP3 by gating on CD4 population using flow cytometry. Cells from with 
and without rapamycin cultures were also stained for isotype antibodies for CD25 and 
FoxP3 and gating was adjusted according to the isotype quadrants. Data is representative 
of at least three independent experiments. 
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Figure 12. 4-1 BB but not CD28 co stimulation is effective III increasing the 
CD25+PoxP3+ T cell proportion. NaIve CD4+ CD2Y T cells from C57BLl6 mice were 
cultured with BALB/c APCs (T cell depleted) and with rapamycin (1 nM) in the presence 
or absence ofIL-2 (25 U/ml). SA-4-1BBL (10 ~g/ml) or anti-CD28 Ab (10 ~g/ml) were 
also added to the culture with or without IL-2. After 4 days, cells were evaluated for 
CD25 and intracellular PoxP3 by gating on CD4 population using flow cytometry. Data 
is representative of at least two independent experiments. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE PERSPECTIVES 
Signaling through TNF receptors play a critical role in modulating adaptive, 
innate and regulatory immunity with important therapeutic implications in settings of 
autoimmunity, transplantation, cancer, and chronic infections. In the context of 
regulatory immunity, signaling via 4-1BB receptor may have diverse and opposing 
consequences and can modulate the development and activity of regulatory T cells. For 
example, we (185) and others (199, 200) have previously demonstrated that signaling via 
4-1BB on naturally occurring Treg cells serves to promote their proliferation and/or 
survival in vitro in the presence of exogenous IL-2. However, signaling via 4-1BB on T 
effector cells antagonizes the suppressive function of of Treg cells thereby endowing 
these cells to be refractory to inhibition by Treg cells (185) via yet to be defined 
mechanisms. Although, the physiological consequence of these opposing effects of 4-
IBB signaling during the course of an immune response is not obvious, it might serve as 
a homeostatic mechanism dictated by the expression kinetics, expression profile on 
various cells and the availability of 4-1 BB and its ligand. This outcome may be regulated 
by transient interaction between 4-1 BBL inducible expressed on APCs with 4-1 BB on 
Treg and Teff cells in the course of ongoing immune responses. The present study 
reveals another important and novel function of 4-1 BB signaling on regulating the 
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balance between adaptive and regulatory immunity. First, when 4-1BBL was used under 
low dose antigenic stimulation or in the presence of TGF -~, it blocked the de novo 
generation of iTreg cells from naIve T cells. Importantly, in the presence of rapamycin, 
4-1 BB signaling played an opposing role by augmenting the conversion of Teff cells into 
iTreg cells. 
Inhibition of the conversion of naIve CD4+ T cells to iTreg cells or augmentation 
of conversion of Teff cells into iTreg cells mediated by 4-1 BB signaling poise this 
pathway with significant potential for therapeutic interventions in setting where Teff and 
Treg cells serve as major culprit of the disease. As shown in Fig. 13, cancer suffers from 
increased number of Treg cells and decreased number of Teff cells that also serve as a 
major barrier for the success of immunotherapeutic interventions. Therefore, modulation 
of 4-1 BB signaling using a well defined approach with the efficacy of effectively 
reversing this balance will have desired therapeutic implications. In marked contrast, in 
the setting of transplantation and autoimmunity where the excess of Teff cells perpetuate 
the disease, reversing the balance of Teff:Treg in favor of Treg cells by exploiting 4-1 BB 
signaling will serve an important therapeutic application. However, given the pleiotropic 
effects of 4-1 BB signaling in the immune system, a better understanding of mechanistic 
basis of how 4-1 BB signaling affects various cells of the immune system and the 
conditions that will allow a controlled manipulation of these effect for therapeutic ends 
will be required to maximize the efficacy over toxicity. 
Accumulating evidence has shown that interaction between 4-1 BB and 4-1 BBL 
plays an important role in controlling T cell function and immune regulation. There are 
still great gaps in our knowledge regarding the activity, expression characteristics and 
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involvement of 4-1 BB signaling on vanous cell types and at vanous stages of the 
immune response during infections. In the case of Treg cell based immunomodulation for 
treatment of cancer and autoimmunity, it is important to know the signaling 
consequences of 4-1BB in controlling the expression of FoxP3. It is also important to 
know the effect and nature of 4-1BB signaling on the proliferation, survival, and 
regulatory function of both nTreg as well as iTreg cells and different mechanisms and the 
signaling utilized by these cells for suppression. Without first understanding how nTreg 
and iTreg cells suppress, it will not be possible to fully understand the differential effects 
of 4-1BB signaling on various subsets of Treg cells as well as Teff cells. Another issue 
that needs to be resolved is whether there are functional differences between nTreg and 
iTreg cells, and the stability of FoxP3 expression on these cell types. It is also important 
to exploit the receptors that are constitutively or inducibly expressed by Treg cells, and 
what role these receptors play in the function of these cells. More studies are are 
required to show the importance of the balance between Teff to Treg cell during various 
immune responses and disease settings. Further research will provide new information 
regarding the potential usefulness of 4-1 BB co stimulation in different therapeutic 
settings. 
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Figure 13. Schematic diagram showing the possible roles played by Treg cells in various 
disease setting and potential interventions by targeting Treg cells. (1) Under normal 
physiological conditions, Treg cells are required in the periphery to control autoreactive 
Teff cells as well as regulating the post-infection Teff cells. (2) In disease setting like 
cancer and autoimmunity, abnormal function of Treg cells exacerbate the disease 
condition. In case of cancer, Treg cells accumulate within the tumor and in the secondary 
lymphoid organs as a result of tumor-mediated recruitment and/or expansion of 
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preexisting nTreg cells or conversion of naive Teff cells into induced iTreg cells. Treg 
cells then suppress anti-tumor immune responses by targeting cells of innate, adaptive, 
and humoral immunity, thereby promoting tumor progression. In case of autoimmunity 
and transplantation, lack of Treg cell number and/or function leads to excessive immune 
response by auto-reactive or allo-antigen specific Teff cells, leading to tissue damage and 
organ failure. (3) The goal of therapeutic interventions in case of cancers is to lower the 
Treg cell number and/or function as well as inhibiting the conversion of naIve CD4+ T 
cells to iTreg cells (shown in this study). This in tum will facilitate an effective Teff cell 
response for eradication of tumors. This has important implications for the treatment of 
cancer that exploits Treg cells for immune evasion and requires a Thl dominated 
response for immunotherapy. In the context of autoimmunity and transplantation, 
increasing the Treg cell number and/or function and enhancing the rate of conversion of 
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